Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 5)
|
BridgeBio Pharma, Inc. (Name of Issuer) |
Common Stock, par value $0.001 per share (Title of Class of Securities) |
10806X102 (CUSIP Number) |
12/31/2024 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
| Rule 13d-1(c)
|
 Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 10806X102 |
| 1 | Names of Reporting Persons
NEIL KUMAR | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
10,466,712.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
5.41 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: (1) Consists of (i) 211,718 shares of Common Stock held directly by Dr. Kumar, (ii) 3,505,322 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of December 31, 2024, (iii) 55,539 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of December 31, 2024, (iv) 5,698,447 shares of Common Stock held by the Kumar Haldea Revocable Trust, of which Dr. Kumar is a co-trustee and (v) 995,686 shares of Common Stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a co-trustee.
(2) Percentage ownership is based on (i) 190,044,473 shares of Common Stock outstanding as of December 31, 2024, (ii) 3,505,322 shares of Common Stock underlying stock options held by Dr. Kumar that are exercisable within 60 days of December 31, 2024 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i) and (iii) 55,539 shares of Common Stock underlying restricted stock units held by Dr. Kumar that are subject to vesting and settlement within 60 days of December 31, 2024 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
BridgeBio Pharma, Inc. | |
| (b) | Address of issuer's principal executive offices:
3160 Porter Street, Suite 250, Palo Alto, CA 94304 | |
| Item 2. | ||
| (a) | Name of person filing:
Neil Kumar | |
| (b) | Address or principal business office or, if none, residence:
3160 Porter Street, Suite 250, Palo Alto, CA 94304 | |
| (c) | Citizenship:
U.S. | |
| (d) | Title of class of securities:
Common Stock, par value $0.001 per share | |
| (e) | CUSIP No.:
10806X102 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
10,466,712 shares of Common Stock, which represents (i) 211,718 shares of Common Stock held of record by Dr. Kumar, (ii) 3,505,322 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of December 31, 2024, (iii) 55,539 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of December 31, 2024, (iv) 5,698,447 shares of Common Stock held of record by Kumar Haldea Revocable Trust and (v) 995,686 shares of Common Stock held of record by the Kumar Haldea Family Irrevocable Trust. | |
| (b) | Percent of class:
5.41 %
| |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
3,772,579 | ||
| (ii) Shared power to vote or to direct the vote:
6,694,133 | ||
| (iii) Sole power to dispose or to direct the disposition of:
3,772,579 | ||
| (iv) Shared power to dispose or to direct the disposition of:
6,694,133 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
Not Applicable
|
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
Comments accompanying signature: Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).